MERCURY BIOPHARMACEUTICAL CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.85 TWD | +12.01% |
|
+30.45% | -15.24% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 4,006 | 7,778 |
| Enterprise Value (EV) 1 | 3,909 | 7,492 |
| P/E ratio | -120 x | -175 x |
| Yield | - | - |
| Capitalization / Revenue | 1,49,49,16,148 x | 7,52,99,95,075 x |
| EV / Revenue | 1,45,86,42,640 x | 7,25,24,29,731 x |
| EV / EBITDA | -13,40,91,252 x | -17,55,04,484 x |
| EV / FCF | -273 x | -182 x |
| FCF Yield | -0.37% | -0.55% |
| Price to Book | 22.2 x | 20 x |
| Nbr of stocks (in thousands) | 4,03,462 | 4,15,962 |
| Reference price 2 | 9.930 | 18.70 |
| Announcement Date | 18/04/23 | 24/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | 2.68 | 1.033 |
| EBITDA | - | -4.327 | -29.15 | -42.69 |
| EBIT 1 | -0.21 | -5.299 | -30.9 | -45.69 |
| Operating Margin | - | - | -1,152.91% | -4,423.04% |
| Earnings before Tax (EBT) 1 | -0.21 | -5.309 | -31.25 | -43.82 |
| Net income 1 | -0.21 | -5.309 | -31.25 | -43.82 |
| Net margin | - | - | -1,166.04% | -4,241.63% |
| EPS 2 | -0.002019 | -0.0200 | -0.0830 | -0.1068 |
| Free Cash Flow 1 | -0.1382 | -10.3 | -14.3 | -41.24 |
| FCF margin | - | - | -533.44% | -3,992.51% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 29/09/22 | 29/09/22 | 18/04/23 | 24/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 0.21 | - | - | - |
| Net Cash position 1 | - | 0.55 | 97.2 | 287 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -0.14 | -10.3 | -14.3 | -41.2 |
| ROE (net income / shareholders' equity) | 202% | -104% | -32.8% | -15.4% |
| ROA (Net income/ Total Assets) | -103% | -49.1% | -15.9% | -8.55% |
| Assets 1 | 0.2032 | 10.8 | 196.9 | 512.5 |
| Book Value Per Share 2 | -0 | 0.0300 | 0.4500 | 0.9300 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0.0800 | 0.1100 |
| Capex | - | 6.98 | - | 12.9 |
| Capex / Sales | - | - | - | 1,251.31% |
| Announcement Date | 29/09/22 | 29/09/22 | 18/04/23 | 24/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.24% | 18Cr | |
| +40.73% | 73TCr | |
| +32.83% | 59TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +4.05% | 28TCr | |
| +15.00% | 24TCr | |
| +9.78% | 21TCr | |
| -5.52% | 20TCr | |
| +6.17% | 16TCr |
- Stock Market
- Equities
- 6932 Stock
- Financials Mercury Biopharmaceutical Corporation
